JAMA:LDL降低水平与患者死亡风险

2018-04-23 zhangfan MedSci原创

研究认为,对于基线LDL水平较高的高胆固醇血症患者,接受强化LDL降低治疗可显著降低死亡及心血管事件风险

近日研究人员就降低低密度脂蛋白胆固醇(LDL-C)药物对减少高胆固醇血症患者死亡以及心血管死亡风险的效果进行了考察。

本次研究为系统综述和荟萃分析研究,收集截止2018年2月的相关研究数据,考察他汀类、依泽类以及PCSK9抑制剂的临床研究效果。采用随机效应回归分析考察基线LDL-C水平以及服药后降低效果与患者死亡风险之间的关系。

34个研究,136?299名患者接受强化LDL降低疗法,133989名患者接受标准LDL降低疗法。强化治疗组与标准治疗组患者全因死亡风险分别减少7.08%和7.70%,但结果随基线LDL水平变化。基线LDL水平较高人群接受强化治疗后死亡率降低显著(基线LDL水平每增加40mg/dL,其比值比改变0.91,绝对风险减少1.05每1000患者年)。强化治疗组与标准治疗组患者心血管死亡风险分别减少3.48%和4.07%,但结果随基线LDL水平变化。基线LDL水平较高人群接受强化治疗后死亡率降低显著(基线LDL水平每增加40mg/dL,其比值比改变0.86,绝对风险减少1.00每1000患者年),但研究仅考察了基线LDL水平超过100 mg/dL的患者。研究发现,基线LDL水平超过160mg/dL人群治疗后全因死亡风险降低最为显著。强化LDL治疗可显著减少基线高LDL水平人群心肌梗死、血管再通和血管紧张症风险。

研究认为,对于基线LDL水平较高的高胆固醇血症患者,接受强化LDL降低治疗可显著降低死亡及心血管事件风险。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1983581, encodeId=d8c31983581f8, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Aug 27 02:05:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255755, encodeId=bf0e1255e557a, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 25 05:05:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422563, encodeId=ea6c142256387, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Wed Apr 25 05:05:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308581, encodeId=0c06308581f7, content=很多血脂不达标, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Mon Apr 23 18:40:27 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1983581, encodeId=d8c31983581f8, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Aug 27 02:05:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255755, encodeId=bf0e1255e557a, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 25 05:05:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422563, encodeId=ea6c142256387, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Wed Apr 25 05:05:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308581, encodeId=0c06308581f7, content=很多血脂不达标, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Mon Apr 23 18:40:27 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1983581, encodeId=d8c31983581f8, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Aug 27 02:05:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255755, encodeId=bf0e1255e557a, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 25 05:05:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422563, encodeId=ea6c142256387, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Wed Apr 25 05:05:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308581, encodeId=0c06308581f7, content=很多血脂不达标, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Mon Apr 23 18:40:27 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
    2018-04-25 zhwj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1983581, encodeId=d8c31983581f8, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Aug 27 02:05:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255755, encodeId=bf0e1255e557a, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 25 05:05:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422563, encodeId=ea6c142256387, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Wed Apr 25 05:05:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308581, encodeId=0c06308581f7, content=很多血脂不达标, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Mon Apr 23 18:40:27 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
    2018-04-23 871538379

    很多血脂不达标

    0

相关资讯

Cell:研究发现抵制高胆固醇的“安全卫士”,胆固醇升高不再怕!

哈佛T.H.Chan公共卫生学院的一个研究小组已经阐明了胆固醇代谢的重要角色,它在细胞中扮演着分子监护者的角色,帮助维持胆固醇水平在一个安全,狭窄的范围内。被称为Nrf1,它既感知和响应过量的胆固醇,并可能代表一个潜在针对胆固醇代谢被破坏的多种疾病的新的治疗靶标。

2018CCCP&SCC:常敏之教授畅谈家族性高胆固醇血症的治疗进展

编者按:2018年4月6日,2018中国医师协会心血管内科医师年会和2018中国南方国际心血管病学术会议“心血管病临床国际论坛Session 2”专场上,来自中国台北荣民总医院的常敏之教授就家族性高胆固醇血症(FH)的治疗进展作了专题解析,让参会者对FH的治疗新药有了更多了解。

Circulation:CHARON研究:他汀早期初始治疗或能使HeFH儿童获益

2017年7月,发表在《Circulation》的一项研究调查了瑞舒伐他汀用于杂合子型家族性高胆固醇血症(HeFH)儿童对颈动脉内膜中层厚度的影响。

Circulation:基因治疗有望攻克家族性高胆固醇血症

来自UCLA和霍华德休斯医学研究院的科学家成功地使用一种抑制胆固醇水平的基因作为家族性高胆固醇血症小鼠斑块治疗的一部分。在这项临床前研究中,研究人员发现,基因LeXis可降低胆固醇和动脉阻塞,该治疗似乎还可减少肝细胞脂肪的积累。这项研究在线发表在杂志《Circulation》上。

JAHA:PCSK9抑制剂对高胆固醇血症患者临床结局的影响!

由此可见,采用PCSK9抑制剂治疗的耐受性良好,能改善心血管预后。尽管在全因或心血管疾病死亡率方面没有发现总体的益处,但基线较高的低密度脂蛋白胆固醇患者可能获益更多。

欧洲已启动高胆固醇血症疫苗1期临床试验

未来防治高胆固醇血症或者就这么简单:打个疫苗就搞定,而且这并不遥远。近期发表于Eur Heart J的一项研究显示,这种新型疫苗即AT04A疫苗在小鼠中实验结果良好,目前已进行I期临床试验。